

|                                      |
|--------------------------------------|
| <b>PATENT ASSIGNMENT COVER SHEET</b> |
|--------------------------------------|

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5403423

|                              |                |
|------------------------------|----------------|
| <b>SUBMISSION TYPE:</b>      | NEW ASSIGNMENT |
| <b>NATURE OF CONVEYANCE:</b> | ASSIGNMENT     |
| <b>SEQUENCE:</b>             | 4              |

**CONVEYING PARTY DATA**

| Name                     | Execution Date |
|--------------------------|----------------|
| VERTA LIFE SCIENCES, LLC | 05/08/2018     |

**RECEIVING PARTY DATA**

|                        |                         |
|------------------------|-------------------------|
| <b>Name:</b>           | DERMAVANT SCIENCES GMBH |
| <b>Street Address:</b> | VIADUKTSTRASSE 8        |
| <b>City:</b>           | BASEL                   |
| <b>State/Country:</b>  | SWITZERLAND             |
| <b>Postal Code:</b>    | 4051                    |

**PROPERTY NUMBERS Total: 1**

| Property Type              | Number   |
|----------------------------|----------|
| <b>Application Number:</b> | 16239719 |

**CORRESPONDENCE DATA**

**Fax Number:** (412)454-5060

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 4124545000

**Email:** docketingpgh@pepperlaw.com

**Correspondent Name:** PEPPER HAMILTON LLP

**Address Line 1:** UNION TRUST BUILDING

**Address Line 2:** 501 GRANT STREET, SUITE 300

**Address Line 4:** PITTSBURGH, PENNSYLVANIA 15219-4429

|                                |                   |
|--------------------------------|-------------------|
| <b>ATTORNEY DOCKET NUMBER:</b> | 143989.00911      |
| <b>NAME OF SUBMITTER:</b>      | PAULA J. WATSON   |
| <b>SIGNATURE:</b>              | /Paula J. Watson/ |
| <b>DATE SIGNED:</b>            | 03/04/2019        |

**Total Attachments: 5**

source=Executed\_Assignment\_Verta\_Dermavant#page1.tif  
 source=Executed\_Assignment\_Verta\_Dermavant#page2.tif  
 source=Executed\_Assignment\_Verta\_Dermavant#page3.tif  
 source=Executed\_Assignment\_Verta\_Dermavant#page4.tif



ASSIGNMENT

This Short Form Patent Assignment (hereinafter referred to as "Assignment") is by and between **VERTA LIFE SCIENCES, LLC**, having an address of 3737 Glenwood Avenue, Suite 100, Raleigh, NC 27612 (hereinafter "Assignor") and **DERMAVANT SCIENCES GMBH**, having an address of Viaduktstrasse 8 - 4051, Basel, Switzerland (hereinafter "Assignee").

WHEREAS, Assignor owns all right, title and interest to certain new and useful invention(s) as set forth and disclosed in the patent application(s) listed in Schedule A attached hereto (hereinafter the "Invention");

WHEREAS, Assignor and Roivant Sciences, Inc. (hereinafter referred to as "Roivant") have entered into that certain Master Services Agreement dated December 23, 2015 (hereinafter referred to as the "Master Services Agreement") pursuant to which Assignor conveyed to Roivant Sciences, Ltd. (hereinafter referred to as "RSL") or its Affiliate as Roivant directs on behalf of RSL all of Assignor's right, title and interest to the Invention and in and to any and all Letters Patent of the United States and foreign countries that may be obtained therefor;

WHEREAS, pursuant to the Master Services Agreement, Roivant directs that the assignment of the Invention shall vest in Assignee; and

WHEREAS, the parties desire to effectuate and confirm such assignment of the Invention pursuant to the terms and conditions set forth herein.

NOW, THEREFORE, for good and valuable consideration, the receipt for and sufficiency of which is hereby acknowledged, at least as of June 7, 2016, Assignor does hereby sell, assign, transfer and set over unto Assignee, its legal representatives, successors, and assigns, Assignor's entire right, title and interest in and to said Invention as set forth in the scheduled application(s), including any applications which claim priority to the scheduled application(s), any application(s) to which the scheduled application(s) claim priority, and any continuations, continuations-in-part, divisions, registrations, reissues, re-examinations or extensions thereof, whether in the U.S. or any foreign country, and in and to any and all patents of the United States and foreign countries which may be issued for said Invention;

AND for good and valuable consideration, the receipt for and sufficiency of which is hereby acknowledged, Assignor does hereby sell, assign, transfer and set over unto Assignee, its legal representatives, successors, and assigns all rights to claim priority rights deriving from the Invention and scheduled application(s); all causes of action and remedies related to the Invention and scheduled application(s) (including, without limitation, the right to sue for past, present, or future infringement, misappropriation or violation of rights related to any of the foregoing and the right to collect royalties and other payments under or on account of any of the foregoing); and any and all other rights and interests arising out of, in connection with, or in relation to the Invention and scheduled application(s).

UPON SAID CONSIDERATION, Assignor shall not execute any writing or do any act whatsoever conflicting with the terms and conditions of this Assignment, and that



DERMAVANT SCIENCES GMBH

Date: March 19, 2017

By: [Signature]

Name: Barbara Ruedler

Title: Head Global Marketing

ATTESTATION

I, the undersigned Civil Law Notary in Basel, Switzerland, \_\_\_\_\_, certify herewith that the signatures attached heretofore are the genuine signatures of \_\_\_\_\_, a citizen of \_\_\_\_\_, residing in \_\_\_\_\_; acting for Axovant Sciences GmbH, in Basel, Switzerland, as \_\_\_\_\_ with single signature.

The authenticity of the signatures was established by means of comparison.

BASEL, Switzerland, this \_\_\_\_\_ day of \_\_\_\_\_, 2017

\_\_\_\_\_  
[SIGNATURE NOTARY PUBLIC]  
S E A L

Leg. Prot. \_\_\_\_\_ / \_\_\_\_\_

**LEGALIZATION**


I, the undersigned Dr. Andreas C. Albrecht, Civil Law Notary in Basel (Switzerland), herewith certify the authenticity of the foregoing signature of Mr. Sascha Bucher, citizen of Flühli LU, Switzerland, residing in Basel, Switzerland, whose signature I have identified by comparison with a doubtlessly authentic signature, the signatory acting on behalf of Dermavant Sciences GmbH, a company which has its registered seat in Basel. The signatory, in his function as chairperson of the managing directors, is individually authorized to legally act on behalf of the aforesaid company.

**IN WITNESS THEREOF** I have put my hand and seal thereunto in Basel (Switzerland) on this 16<sup>th</sup> (sixteenth) day of March, 2018 (two thousand and eighteen).

*A. Albrecht,*  
*Notar*

Leg. Prot. 138/2018

| APOSTILLE  |  |
|--|--|
| (Convention de la Haye du 5 octobre 1961)                                    |  |
| 1. Country / Land  | Swiss Confederation, Canton of Basel-City / Schweizerische Eidgenossenschaft, Kanton Basel-Stadt |
| This public document / Diese öffentliche Urkunde                             |  |
| 2. has been signed by / ist unterschrieben von                               | Dr. iur. Andreas C. Albrecht   |
| 3. acting in the capacity of / in seiner Eigenschaft als                     | Notary Public  |
| 4. bears the stamp/seal of / Sie ist versehen mit dem Stempel/Siegel des/der | Albrecht Andreas C.  |
| Certified / Bestätigt  |  |
| 5. at / in   | Basel  |
| 6. the / am  | 16.03.2018   |
| 7. by the / durch das  | Legalisation Office of the Canton of Basel-City / Beglaubigungsbüro des Kantons Basel-Stadt      |
| 8. No. / Nr.   | 123429   |
| 9. stamp/seal / Stempel/Siegel   | tax / Taxe CHF 20.00   |
| 10. Signature / Unterschrift   | Aisha Luisoni  |



*A. L.*

## SCHEDULE A

| Country | Patent Application No. | Filing Date      | Title   | Inventors   |
|---------|------------------------|------------------|---|---|
| US      | 62/347,006             | June 7, 2016     | TOPICAL FORMULATIONS OF PDE-4 INHIBITORS AND THEIR METHODS OF USE | Ambrish VYAS<br>Seiji TAKEMOTO<br>Yoshihiro AKIMOTO |
| US      | 62/449,753             | January 24, 2017 | TOPICAL FORMULATIONS OF PDE-4 INHIBITORS AND THEIR METHODS OF USE | Ambrish VYAS<br>Seiji TAKEMOTO<br>Yoshihiro AKIMOTO |
| US      | 62/488,495             | April 21, 2017   | TOPICAL FORMULATIONS OF PDE-4 INHIBITORS AND THEIR METHODS OF USE | Ambrish VYAS<br>Seiji TAKEMOTO<br>Yoshihiro AKIMOTO |
| US      | 15/616,405             | June 7, 2017     | TOPICAL FORMULATIONS OF PDE-4 INHIBITORS AND THEIR METHODS OF USE | Ambrish VYAS<br>Seiji TAKEMOTO<br>Yoshihiro AKIMOTO |
| WO      | PCT/US2017/036381      | June 7, 2017     | TOPICAL FORMULATIONS OF PDE-4 INHIBITORS AND THEIR METHODS OF USE | Ambrish VYAS<br>Seiji TAKEMOTO<br>Yoshihiro AKIMOTO |